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PreviewsJavor et al. For example, the mouse LPS
model of NASH may be a special case,
mouse NASH may be fundamentally
a poor model of human NASH, or the
NASH in lipodystrophy may be unrepre-
sentative of ‘‘typical’’ NASH due to inade-
quate adipose tissue storage capacity. To
determine which (if any) of these explana-
tions is correct will require a deeper
understanding of NASH.
A starting point might be detailed phe-
notyping and classification of NAFLD
using criteria in addition tomedical history
and histology. Comparison with cancer is
illustrative: by exquisitely genotyping and
phenotyping cancers, treatments can
now be tailored, thus yielding a higher
probability of treatment success and
less toxicity. A similar analysis of NAFLD
may identify subclasses of the disease
with unique immune, inflammatory, and
metabolic characteristics and may reveal
whether leptin plays the same or different
roles in each type. Genetic screens have
now identified six loci that contribute to
variance in NAFLD traits (e.g., Romeo2 Cell Metabolism 16, July 3, 2012 ª2012 Elset al., 2008; Speliotes et al., 2011), with
one increasing hepatic triglyceride
production (Kumari et al., 2012), suggest-
ing that further phenotyping efforts will be
fruitful. It seems likely that integrating
phenotypic and genetic information with
mechanistic studies will help unravel the
conundrum that is NASH. In summary,
Imajo et al. make a strong case that leptin
contributes to NASH in a mouse endo-
toxin model of NASH. This interesting
result will spur examination of the gener-
ality of the contribution of leptin in other
NASH models and drive more detailed
mechanistic studies of NAFLD.
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How adenosine receptors protect the ischemic heart is not completely understood. Eckle et al. (2012) now
show that signaling through adenosine receptor 2b (Adora2b) stabilizes a circadian rhythm protein, period
2 (Per2), resulting in the stabilization of hypoxia-inducible factor-1a (HIF-1a), upregulation of glycolysis,
and cardioprotection from ischemia.Myocardial ischemia results in dramatic
metabolic perturbations, due primarily
to a mismatch between cardiac muscle
oxygen supply and demand. The ensuing
deficits in ATP production can lead to
cardiac myocyte cell death. As such,
considerable efforts have focused on
modulating cardiac energy metabolism
as an approach to treat myocardial
ischemia. In addition to the many
approaches aimed at increasing energy
supply or decreasing energy demand,
novel approaches include switching theheart to a more ‘‘oxygen-efficient’’ utiliza-
tion of energy substrates (Lopaschuk
et al., 2010). Adenosine receptor signaling
has been extensively studied as an
approach to treat myocardial ischemia
(Eckle et al., 2008), with favorable alter-
ations in cardiac energy metabolism
contributing to the cardioprotective effi-
cacy of adenosine receptor activation
(Finegan et al., 1996).
A recent study (Eckle et al., 2012)
provides important insights into the sig-
naling pathways by which adenosinereceptor 2b (Adora2b) activation medi-
ates cardioprotection. The authors dem-
onstrate a selective upregulation of
Adora2b in clinical samples from patients
with ischemic heart disease. To delineate
the signaling pathways downstream of
Adora2b activation and their potential
role in cardioprotection the authors em-
ployed an ischemic preconditioning (IPC)
protocol (adenosine receptor activation
has been identified as a key component
of IPC), where brief, sublethal periods of
ischemia and reperfusion, prior to a
Figure 1. A Model for the Stimulation of Glycolysis in the Heart by Adora2b
Binding of adenosine to Adora2b increases cAMP levels and inhibits CUL 1 (via deneddylation). This
results in an increase in phosphorylation of CREB, increased transcript induction of the circadian rhythm
protein period 2 (Per2), and a stabilization of Per2 via proteasomal inhibition due to decreased ubiquitina-
tion of Per2. Increased levels of Per2 then stabilize HIF-1a, resulting in an induction of glycolytic enzymes
and a stimulation of glycolysis. In parallel, a decrease in mitochondrial TCA cycle activity is observed.
The increase in glycolysis may enable a more ‘‘oxygen-efficient’’ energy metabolism, affording cardiopro-
tection to the heart during and following ischemia. Abbreviations: Adora2b, adenosine receptor 2b; cAMP,
30-50 cyclic adenosine monophosphate; CREB, cAMP response element-binding protein; pCREB, phos-
phorylated cAMP response element-binding protein; CUL 1, cullin 1; HIF-1a, hypoxia-inducible factor-1a;
NEDD8, ubiquitin-like polypeptide Nedd8; Per2, period 2; TCA, tricarboxylic acid.
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Previewsprolonged, and otherwise lethal period of
ischemia, decrease cardiac ischemia-re-
perfusion injury (Murry et al., 1986). RNA
microarray and canonical pathway anal-
ysis identified the circadian rhythm
protein, Per2, as exhibiting the highest
differential readout (upregulation), be-
tween wild-type (WT) and Adora2b/
mice subjected to cardiac IPC. The
authors then demonstrate that Adora2b
activation stabilizes Per2 by preventing
its proteasomal degradation. Further-
more, they show that Per2, in turn,
promotes the stabilization of hypoxia-
inducible factor-1a (HIF-1a), leading to
the induction of HIF-1a-target genes,
including those encoding glycolytic
enzymes. Importantly, the stabilization of
HIF-1a and the upregulation of glycolysis
seen with Adora2b stimulation and IPC
were abolished in per2/mice, demon-
strating that Per2 is required for the
effects of IPC and Adora2b on glycolysis.
Together these results show that thispathway enhances the glycolytic capacity
of the ischemic heart, and the authors
propose that this enhancement of glycol-
ysis increases cardiac efficiency and the
ability of the heart to adapt to ischemia.
Combined, these data provide compelling
evidence for a link between Adora2b acti-
vation, Per2 and HIF-1a stabilization,
enhanced glycolysis, and cardioprotec-
tion (Figure 1).
A possible role for circadian rhythm in
modulating ischemic injury was sug-
gested by previous studies demon-
strating that the extent of myocardial
infarction is larger in the early-morning
hours (Reiter et al., 2012). The involve-
ment of a circadian rhythm protein (Per2)
in modulating ischemic injury, as well as
the observation that HIF-1a has a circa-
dian pattern of expression, further impli-
cates circadian-rhythm changes as a
causative factor for the larger infarcts in
patients suffering a myocardial infarction
in the early morning (Eckle et al., 2012).Cell MetaboHowever, the circadian oscillations of
Per2 and HIF-1a proteins do not neces-
sarily correlate with the timing of the
increased infarct size observed in humans
(Sua´rez-Barrientos et al., 2011). Interest-
ingly, the authors did observe an increase
in Per2 expression in patients with
ischemic heart disease (Eckle et al.,
2012), but did not test for potential circa-
dian oscillations in Per2 expression.
Whether the increase in Per2 expression
in these patients is an adaptive response
to ischemia or a nonspecific conse-
quence also remains to be determined.
While increases in glycolysis have been
linked to ischemic cardioprotection (Ash-
rafian et al., 2007), the role of glycolysis
in adaptation to ischemia is not straight-
forward. During ischemia, the decrease
in mitochondrial oxidative metabolism
(due to oxygen limitation) results in an un-
coupling of glycolysis from glucose oxida-
tion, and the production of lactate, and H+
ions from the hydrolysis of glycolytically
derived ATP (Lopaschuk et al., 2010). As
a result, while enhancing glycolysis can
produce ATPwithout the need for oxygen,
glycolysis can also be a major source of
acidosis during and following ischemia.
Not only can acidosis decrease cardiac
efficiency (as ATP is redirected toward
pathways that clear the H+ and re-estab-
lish ionic homeostasis in the cardiac myo-
cyte), it can also contribute to cell death, if
severe. Under ideal conditions, therefore,
glycolysis is coupled to glucose oxidation
(i.e., the subsequent oxidation of the pyru-
vate derived from glycolysis) and neither
lactate nor H+ accumulate in the heart.
This issue of glycolysis and glucose
oxidation has interesting implications
with regards to the downstream signaling
of Adora2b and Per2. The data of Eckle
et al. (2012) show that glycolytic enzyme
induction and glycolysis during reperfu-
sion following ischemia is impaired in
per2/mice, yet the subsequent oxida-
tion of glucose (measured using 13C-
glucose isotopomer analysis) is actually
increased, an effect that should improve
the coupling between glycolysis and
glucose oxidation. Furthermore, stimu-
lating glucose oxidation has been demon-
strated to limit ischemia-reperfusion injury
and decrease myocardial infarct size
(Ussher et al., 2012), and may contribute
to the cardioprotection in per2/mice
observed by others (Virag et al., 2010).
Eckle et al. (2012) also demonstratedlism 16, July 3, 2012 ª2012 Elsevier Inc. 3
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Previewsthat increases in HIF-1a levels were asso-
ciated with an increase in pyruvate dehy-
drogenase kinase 1 levels, which would
be expected to inhibit glucose oxidation,
since this kinase phosphorylates and
inhibits the rate-limiting enzyme for
glucose oxidation, pyruvate dehydroge-
nase. These results suggest that the
Adora2b and Per2 signaling pathway,
while increasing glycolysis, may actually
impair glucose oxidation (Figure 1), as
Per 2 deletion appears to enhance
glucose oxidation. How the increase in
glycolysis together with the probable
decrease in glucose oxidation affects
cardiac function during reperfusion
following ischemia will require further
clarification.
The effects of adenosine and adeno-
sine receptor activation on cardiac glu-
cose metabolism have been extensively
studied. Activation of either adenosine
receptor, Adora1 or Adora2, provides
cardioprotection. Yet, Adora1, unlike
Adora2, decreases glycolytic rates in the4 Cell Metabolism 16, July 3, 2012 ª2012 Elsheart and improves coupling between
glycolysis and glucose oxidation (Finegan
et al., 1996). On the surface, these results
appear to be at odds with the cardiopro-
tection observed with Adora2b stimula-
tion, which, as shown by Eckle et al.
(2012), promotes glycolysis in the heart.
As such, further studies are necessary to
examine the relationship between adeno-
sine receptor signaling, glucose metabo-
lism, and cardioprotection. Nevertheless,
the involvement of Per2 and HIF-1a, and
the potential circadian rhythm of this
pathway provide important insights into
the control of glycolysis, and the potential
role of these changes in adaptation to
myocardial ischemia.
REFERENCES
Ashrafian, H., Frenneaux, M.P., and Opie, L.H.
(2007). Circulation 116, 434–448.
Eckle, T., Hartmann, K., Bonney, S., Reithel, S.,
Mittelbronn, M., Walker, L.A., Lowes, B.D., Han,
J., Borchers, C.H., Buttrick, P.M., et al. (2012).
Nat. Med. 18, 774–782.evier Inc.Eckle, T., Ko¨hler, D., Lehmann, R., El Kasmi, K.,
and Eltzschig, H.K. (2008). Circulation 118,
166–175.
Finegan, B.A., Lopaschuk, G.D., Gandhi, M., and
Clanachan, A.S. (1996). Br. J. Pharmacol. 118,
355–363.
Lopaschuk, G.D., Ussher, J.R., Folmes, C.D.,
Jaswal, J.S., and Stanley, W.C. (2010). Physiol.
Rev. 90, 207–258.
Murry, C.E., Jennings, R.B., and Reimer, K.A.
(1986). Circulation 74, 1124–1136.
Reiter, R., Swingen, C., Moore, L., Henry, T.D., and
Traverse, J.H. (2012). Circ. Res. 110, 105–110.
Sua´rez-Barrientos, A., Lo´pez-Romero, P., Vivas,
D., Castro-Ferreira, F., Nu´n˜ez-Gil, I., Franco, E.,
Ruiz-Mateos, B., Garcı´a-Rubira, J.C., Ferna´ndez-
Ortiz, A., Macaya, C., and Ibanez, B. (2011). Heart
97, 970–976.
Ussher, J.R., Wang, W., Gandhi, M., Keung, W.,
Samokhvalov, V., Oka, T., Wagg, C.S., Jaswal,
J.S., Harris, R.A., Clanachan, A.S., et al. (2012).
Cardiovasc. Res. 94, 359–369.
Virag, J.A., Dries, J.L., Easton, P.R., Friesland,
A.M., DeAntonio, J.H., Chintalgattu, V., Cozzi, E.,
Lehmann, B.D., Ding, J.M., and Lust, R.M. (2010).
Am. J. Physiol. Heart Circ. Physiol. 298, H1088–
H1095.Regulatory T Cells Expressing
PPAR-g Control Inflammation in ObesityMasahide Hamaguchi1,2 and Shimon Sakaguchi1,2,*
1Department of Experimental Immunology, WPI Immunology Frontier Research Center, Osaka University, Suita 565-0871, Japan
2Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
*Correspondence: shimon@ifrec.osaka-u.ac.jp
http://dx.doi.org/10.1016/j.cmet.2012.06.007
A recent study (Cipolletta et al., 2012) shows that regulatory T (Treg) cells expressing the peroxisome-prolif-
erator- activated receptor (PPAR-g) are engaged in suppressing adipose tissue inflammation in obesity, sug-
gesting that Treg cells may be a target for treatment and prevention of adipose tissue inflammation and
insulin resistance.In obesity, enlarged adipocytes accumu-
lating in visceral adipose tissue (VAT) elicit
infiltration of macrophages and other
immune cells (Feuerer et al., 2009, Winer
et al., 2009, Nishimura et al., 2009,Olefsky
and Glass, 2010). These cells secrete
proinflammatory cytokines and mediate
chronic low-grade inflammation in VAT.
The inflamed adipose tissue, in turn, may
release cytokines, adipokines, fatty acids,
and other substances that may affectother organs, such as liver and muscle,
leading to systemic insulin resistance. A
recent study from Cipolletta and
colleagues reveals an important role for
VAT-specific natural Treg cells in the
suppressionof obesity-associated inflam-
mation in VAT and consequently in
combatting insulin resistance (Cipolletta
et al., 2012).
Naturally occurring Treg cells are a
unique CD4+ T cell subpopulation specifi-cally adapted to the suppression of
aberrant or excessive immune responses
that are harmful to the host (Sakaguchi
et al., 2008). In physiological conditions,
they constitute 10% of peripheral CD4+
Tcellsandarecharacterizedby theexpres-
sion of the transcription factor Foxp3. The
majority of Foxp3+ CD4+ Treg cells are
produced by the thymus as a functionally
mature and distinct T cell subpopulation,
although naive conventional T cells can
